EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Mechanisms of Response and Resistance to Immune Checkpoint Inhibitors in Renal Cell Carcinoma

Martina Milella, Francesco Lasorsa, Monica Rutigliano, Alessandro Caniglia, Emanuele Naglieri, Savio Domenico Pandolfo, Pasquale Ditonno, Giuseppe Lucarelli iD

Cells · 2026

DOI: 10.3390/cells15211954 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, 2026. Verfasst von Martina Milella und 7 weiteren Autor:innen. Beteiligte Einrichtung: Urology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", 70124 Bari, Italy. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Immune Checkpoint Inhibitors, Kidney Neoplasms, Drug Resistance, Neoplasm. Die Arbeit nennt 188 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Renal cell carcinoma (RCC), particularly its clear-cell subtype (ccRCC), is characterized by metabolic reprogramming and a complex tumor microenvironment that influence responses to immune checkpoint inhibitors (ICIs). Despite clinical advances, therapeutic resistance remains a major hurdle. Here we review the molecular determinants governing ccRCC sensitivity and resistance to ICIs, integrating insights from genomic alterations such as PBRM1 and BAP1 mutations, immune cell exhaustion dynamics, stromal and metabolic barriers, and the role of endogenous retroviral antigens. We discuss how these factors modulate immune evasion and impact therapeutic outcomes. Emerging strategies including biomarker-driven patient stratification, HIF-2α inhibition, and personalized immunotherapies show promise in overcoming resistance. Our synthesis highlights the necessity of multi-omics approaches to tailor immunotherapy, aiming to enhance durable responses and survival in ccRCC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellImmune Checkpoint InhibitorsKidney NeoplasmsDrug Resistance, NeoplasmHumansTumor MicroenvironmentImmunotherapyAnimalsTumor Suppressor Proteins

Stichwörter der Autor:innen

biomarkersimmune checkpoint inhibitorsimmunotherapy resistancerenal cell carcinomatumor microenvironment

Substanzen

Immune Checkpoint InhibitorsTumor Suppressor Proteins

Autor:innen und Institutionen

  • Urology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", 70124 Bari, Italy.
  • Urology and Kidney Transplantation Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro", 70124 Bari, Italy.
  • Pathology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", 70124 Bari, Italy.
  • Oncology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", 70124 Bari, Italy.
  • Department of Urology, University of L'Aquila, 67100 L'Aquila, Italy.
  • Department of Neurosciences, Science of Reproduction and Odontostomatology, Federico II University, 80138 Naples, Italy.

ORCID-Profile: Giuseppe Lucarelli

Zitieren

APA

Milella, M., Lasorsa, F., Rutigliano, M., Caniglia, A., Naglieri, E., Pandolfo, S. D., Ditonno, P., & Lucarelli, G. (2026). Mechanisms of Response and Resistance to Immune Checkpoint Inhibitors in Renal Cell Carcinoma. Cells. https://doi.org/10.3390/cells15211954

Vancouver

Milella M, Lasorsa F, Rutigliano M, Caniglia A, Naglieri E, Pandolfo SD, et al. Mechanisms of Response and Resistance to Immune Checkpoint Inhibitors in Renal Cell Carcinoma. Cells. 2026. doi:10.3390/cells15211954

BibTeX
@article{Milella2026,
  author = {Milella, Martina and Lasorsa, Francesco and Rutigliano, Monica and Caniglia, Alessandro and Naglieri, Emanuele and Pandolfo, Savio Domenico and Ditonno, Pasquale and Lucarelli, Giuseppe},
  title = {Mechanisms of Response and Resistance to Immune Checkpoint Inhibitors in Renal Cell Carcinoma},
  journal = {Cells},
  year = {2026},
  doi = {10.3390/cells15211954}
}
Kostenlos starten →